PDF herunterladen
Semin Respir Crit Care Med 2022; 43(02): 175-182
DOI: 10.1055/s-0041-1742105
Review Article

Pharmacokinetic/Pharmacodynamic Optimization of Hospital-Acquired and Ventilator-Associated Pneumonia: Challenges and Strategies

Yasmeen P. Abouelhassan
1   Center for Anti-Infective Research and Development, Hartford Hospital, Hartford, Connecticut
,
David Nicolau
1   Center for Anti-Infective Research and Development, Hartford Hospital, Hartford, Connecticut
2   Division of Infectious Diseases, Hartford Hospital, Hartford, Connecticut
› Institutsangaben
› Weitere Informationen
    Lizenzen und Reprints

Abstract

Hospital-acquired pneumonia (HAP) and ventilator-associated pneumonia (VAP) are correlated with high mortality rates worldwide. Thus, the administration of antibiotic therapy with appropriate dosing regimen is critical. An efficient antibiotic is needed to maintain an adequate concentration at the infection site, for a sufficient period of time, to achieve the best therapeutic outcome. It can, however, be challenging for antibiotics to penetrate the pulmonary system due to the complexity of its structure. Crossing the blood alveolar barrier is a difficult process determined by multiple factors that are either drug related or infection related. Thus, the understanding of pharmacokinetics/pharmacodynamics (PK/PD) of antibiotics identifies the optimum dosing regimens to achieve drug penetration into the epithelial lining fluid at adequate therapeutic concentrations. Critically ill patients in the ICU can express augmented renal clearance (ARC), characterized by enhanced renal function, or may have renal dysfunction necessitating supportive care such as continuous renal replacement therapy (CRRT). Both ARC and CRRT can alter drug elimination, thus affecting drug concentrations. PK of critically ill patients is less clear due to the multiple variabilities associated with their condition. Therefore, conventional dosing regimens often lead to therapeutic failure. Another major hurdle faced in optimizing treatment for HAP/VAP is the reduction of the in vitro potency. Therapeutic drug monitoring (TDM), if available, may allow health care providers to personalize treatment to maximize efficacy of the drug exposures while minimizing toxicity. TDM can be of significant importance in populations whom PK are less defined and for resistant infections to achieve the best therapeutic outcome.

Keywords

nosocomial pneumonia - pharmacokinetics/pharmacodynamics - drug optimization - augmented renal clearance - continuous renal replacement therapy - antibiotic resistance - therapeutic drug monitoring


Publikationsverlauf

Artikel online veröffentlicht:
27. Januar 2022

© 2022. Thieme. All rights reserved.

Thieme Medical Publishers, Inc.
333 Seventh Avenue, 18th Floor, New York, NY 10001, USA

 

  • References

  • 1 Kalil AC, Metersky ML, Klompas M. et al. Management of adults with hospital-acquired and ventilator-associated pneumonia: 2016 Clinical Practice Guidelines by the Infectious Diseases Society of America and the American Thoracic Society. Clin Infect Dis 2016; 63 (05) e61-e111
    CrossrefPubMedGoogle Scholar
  • 2 Govindan S, Hyzy RC. The 2016 guidelines for hospital-acquired and ventilator-associated pneumonia. A selection correction?. Am J Respir Crit Care Med 2016; 194 (06) 658-660
    CrossrefPubMedGoogle Scholar
  • 3 Mandell LA, Rubinstein E. HAP/VAP: simpler may be better. Can J Infect Dis Med Microbiol 2008; 19 (01) 11
    CrossrefPubMedGoogle Scholar
  • 4 Motos A, Kidd JM, Nicolau DP. Optimizing antibiotic administration for pneumonia. Clin Chest Med 2018; 39 (04) 837-852
    CrossrefPubMedGoogle Scholar
  • 5 Drusano GL. Role of pharmacokinetics in the outcome of infections. Antimicrob Agents Chemother 1988; 32 (03) 289-297
    CrossrefPubMedGoogle Scholar
  • 6 Drusano GL. Pharmacokinetics and pharmacodynamics of antimicrobials. Clin Infect Dis 2007; 45 (Suppl. 01) S89-S95
    CrossrefPubMedGoogle Scholar
  • 7 Sy SK, Zhuang L, Derendorf H. Pharmacokinetics and pharmacodynamics in antibiotic dose optimization. Expert Opin Drug Metab Toxicol 2016; 12 (01) 93-114
    CrossrefPubMedGoogle Scholar
  • 8 Derendorf H, Lesko LJ, Chaikin P. et al. Pharmacokinetic/pharmacodynamic modeling in drug research and development. J Clin Pharmacol 2000; 40 (12 Pt 2): 1399-1418
    CrossrefPubMedGoogle Scholar
  • 9 Meibohm B, Derendorf H. Basic concepts of pharmacokinetic/pharmacodynamic (PK/PD) modelling. Int J Clin Pharmacol Ther 1997; 35 (10) 401-413
    PubMedGoogle Scholar
  • 10 Onufrak NJ, Forrest A, Gonzalez D. Pharmacokinetic and pharmacodynamic principles of anti-infective dosing. Clin Ther 2016; 38 (09) 1930-1947
    CrossrefPubMedGoogle Scholar
  • 11 Peck RW, Shahin MH, Vinks AA. Precision dosing: the clinical pharmacology of Goldilocks. Clin Pharmacol Ther 2021; 109 (01) 11-14
    CrossrefPubMedGoogle Scholar
  • 12 Gill CM, Aktaş E, Alfouzan W. et al; ERACE-PA Global Study Group. Elevated MICs of susceptible antipseudomonal cephalosporins in non-carbapenemase-producing, carbapenem-resistant Pseudomonas aeruginosa: implications for dose optimization. Antimicrob Agents Chemother 2021; 65 (11) e0120421
    CrossrefPubMedGoogle Scholar
  • 13 Drusano GL. What are the properties that make an antibiotic acceptable for therapy of community-acquired pneumonia?. J Antimicrob Chemother 2011; 66 (Suppl. 03) iii61-iii67
    PubMedGoogle Scholar
  • 14 Dhanani J, Roberts JA, Chew M. et al. Antimicrobial chemotherapy and lung microdialysis: a review. Int J Antimicrob Agents 2010; 36 (06) 491-500
    CrossrefPubMedGoogle Scholar
  • 15 Baldwin DR, Honeybourne D, Wise R. Pulmonary disposition of antimicrobial agents: in vivo observations and clinical relevance. Antimicrob Agents Chemother 1992; 36 (06) 1176-1180
    CrossrefPubMedGoogle Scholar
  • 16 Zeitlinger M, Müller M, Joukhadar C. Lung microdialysis—a powerful tool for the determination of exogenous and endogenous compounds in the lower respiratory tract (mini-review). AAPS J 2005; 7 (03) E600-E608
    CrossrefPubMedGoogle Scholar
  • 17 Nix DE. Intrapulmonary concentrations of antimicrobial agents. Infect Dis Clin North Am 1998; 12 (03) 631-646 , viii
    CrossrefPubMedGoogle Scholar
  • 18 Honeybourne D. Antibiotic penetration in the respiratory tract and implications for the selection of antimicrobial therapy. Curr Opin Pulm Med 1997; 3 (02) 170-174
    CrossrefPubMedGoogle Scholar
  • 19 Rodvold KA, George JM, Yoo L. Penetration of anti-infective agents into pulmonary epithelial lining fluid: focus on antibacterial agents. Clin Pharmacokinet 2011; 50 (10) 637-664
    CrossrefPubMedGoogle Scholar
  • 20 Kiem S, Schentag JJ. Interpretation of antibiotic concentration ratios measured in epithelial lining fluid. Antimicrob Agents Chemother 2008; 52 (01) 24-36
    CrossrefPubMedGoogle Scholar
  • 21 Baldwin DR, Wise R, Andrews JM, Gill M, Honeybourne D. Comparative bronchoalveolar concentrations of ciprofloxacin and lomefloxacin following oral administration. Respir Med 1993; 87 (08) 595-601
    CrossrefPubMedGoogle Scholar
  • 22 Panteix G, Harf R, Desnottes JF. et al. Accumulation of pefloxacin in the lower respiratory tract demonstrated by bronchoalveolar lavage. J Antimicrob Chemother 1994; 33 (05) 979-985
    CrossrefPubMedGoogle Scholar
  • 23 Kikuchi J, Yamazaki K, Kikuchi E, Ishizaka A, Nishimura M. Pharmacokinetics of gatifloxacin after a single oral dose in healthy young adult subjects and adult patients with chronic bronchitis, with a comparison of drug concentrations obtained by bronchoscopic microsampling and bronchoalveolar lavage. Clin Ther 2007; 29 (01) 123-130
    CrossrefPubMedGoogle Scholar
  • 24 Allegranzi B, Cazzadori A, Di Perri G. et al. Concentrations of single-dose meropenem (1 g iv) in bronchoalveolar lavage and epithelial lining fluid. J Antimicrob Chemother 2000; 46 (02) 319-322
    CrossrefPubMedGoogle Scholar
  • 25 Baldwin DR, Andrews JM, Wise R, Honeybourne D. Bronchoalveolar distribution of cefuroxime axetil and in-vitro efficacy of observed concentrations against respiratory pathogens. J Antimicrob Chemother 1992; 30 (03) 377-385
    CrossrefPubMedGoogle Scholar
  • 26 Meyer KC, Raghu G, Baughman RP. et al; American Thoracic Society Committee on BAL in Interstitial Lung Disease. An official American Thoracic Society clinical practice guideline: the clinical utility of bronchoalveolar lavage cellular analysis in interstitial lung disease. Am J Respir Crit Care Med 2012; 185 (09) 1004-1014
    CrossrefPubMedGoogle Scholar
  • 27 Aulin LBS, Valitalo PA, Rizk ML. et al. Validation of a model predicting anti-infective lung penetration in the epithelial lining fluid of humans. Pharm Res 2018; 35 (02) 26
    CrossrefPubMedGoogle Scholar
  • 28 Veiga RP, Paiva JA. Pharmacokinetics-pharmacodynamics issues relevant for the clinical use of beta-lactam antibiotics in critically ill patients. Crit Care 2018; 22 (01) 233
    CrossrefPubMedGoogle Scholar
  • 29 MacGowan A. Revisiting Beta-lactams—PK/PD improves dosing of old antibiotics. Curr Opin Pharmacol 2011; 11 (05) 470-476
    CrossrefPubMedGoogle Scholar
  • 30 Williams P, Cotta MO, Roberts JA. Pharmacokinetics/pharmacodynamics of β-lactams and therapeutic drug monitoring: from theory to practical issues in the intensive care unit. Semin Respir Crit Care Med 2019; 40 (04) 476-487
    Artikel in Thieme ConnectPubMedGoogle Scholar
  • 31 Kotapati S, Kuti JL, Nightingale CH, Nicolau DP. Role of pharmacodynamics in designing dosage regimens for beta-lactams. Conn Med 2003; 67 (05) 265-268
    PubMedGoogle Scholar
  • 32 Gillespie EL, Kuti JL, Nicolau DP. Pharmacodynamics of antimicrobials: treatment optimisation. Expert Opin Drug Metab Toxicol 2005; 1 (03) 351-361
    CrossrefPubMedGoogle Scholar
  • 33 MacVane SH, Kuti JL, Nicolau DP. Prolonging β-lactam infusion: a review of the rationale and evidence, and guidance for implementation. Int J Antimicrob Agents 2014; 43 (02) 105-113
    CrossrefPubMedGoogle Scholar
  • 34 Fratoni AJ, Nicolau DP, Kuti JL. A guide to therapeutic drug monitoring of β-lactam antibiotics. Pharmacotherapy 2021; 41 (02) 220-233
    CrossrefPubMedGoogle Scholar
  • 35 Vogelman BS, Craig WA. Postantibiotic effects. J Antimicrob Chemother 1985; 15 (suppl A): 37-46
    CrossrefPubMedGoogle Scholar
  • 36 Vogelman B, Craig WA. Kinetics of antimicrobial activity. J Pediatr 1986; 108 (5 Pt 2): 835-840
    CrossrefPubMedGoogle Scholar
  • 37 Turnidge JD. The pharmacodynamics of beta-lactams. Clin Infect Dis 1998; 27 (01) 10-22
    CrossrefPubMedGoogle Scholar
  • 38 Craig WA. Pharmacokinetic/pharmacodynamic parameters: rationale for antibacterial dosing of mice and men. Clin Infect Dis 1998; 26 (01) 1-10 , quiz 11–12
    CrossrefPubMedGoogle Scholar
  • 39 Cusumano JA, Klinker KP, Huttner A, Luther MK, Roberts JA, LaPlante KL. Towards precision medicine: therapeutic drug monitoring-guided dosing of vancomycin and β-lactam antibiotics to maximize effectiveness and minimize toxicity. Am J Health Syst Pharm 2020; 77 (14) 1104-1112
    CrossrefPubMedGoogle Scholar
  • 40 Xiao AJ, Miller BW, Huntington JA, Nicolau DP. Ceftolozane/tazobactam pharmacokinetic/pharmacodynamic-derived dose justification for phase 3 studies in patients with nosocomial pneumonia. J Clin Pharmacol 2016; 56 (01) 56-66
    CrossrefPubMedGoogle Scholar
  • 41 Caro L, Nicolau DP, De Waele JJ. et al. Lung penetration, bronchopulmonary pharmacokinetic/pharmacodynamic profile and safety of 3 g of ceftolozane/tazobactam administered to ventilated, critically ill patients with pneumonia. J Antimicrob Chemother 2020; 75 (06) 1546-1553
    CrossrefPubMedGoogle Scholar
  • 42 Gatti M, Pea F. Continuous versus intermittent infusion of antibiotics in gram-negative multidrug-resistant infections. Curr Opin Infect Dis 2021; 34 (06) 737-747
    CrossrefPubMedGoogle Scholar
  • 43 Benítez-Cano A, Luque S, Sorlí L. et al. Intrapulmonary concentrations of meropenem administered by continuous infusion in critically ill patients with nosocomial pneumonia: a randomized pharmacokinetic trial. Crit Care 2020; 24 (01) 55
    CrossrefPubMedGoogle Scholar
  • 44 Lal A, Jaoude P, El-Solh AA. Prolonged versus intermittent infusion of β-lactams for the treatment of nosocomial pneumonia: a meta-analysis. Infect Chemother 2016; 48 (02) 81-90
    CrossrefPubMedGoogle Scholar
  • 45 Dulhunty JM, Roberts JA, Davis JS. et al. Continuous infusion of beta-lactam antibiotics in severe sepsis: a multicenter double-blind, randomized controlled trial. Clin Infect Dis 2013; 56 (02) 236-244
    CrossrefPubMedGoogle Scholar
  • 46 Ruiz J, Ferrada A, Salavert M. et al. Ceftolozane/tazobactam dosing requirements against Pseudomonas aeruginosa bacteremia. Dose Response 2020; 18 (01) 1559325819885790
    CrossrefPubMedGoogle Scholar
  • 47 Tamma PD, Beisken S, Bergman Y. et al. Modifiable risk factors for the emergence of ceftolozane-tazobactam resistance. Clin Infect Dis 2021; Dec 6; 73 (11) e4599-e4606
    CrossrefPubMedGoogle Scholar
  • 48 Tumbarello M, Raffaelli F, Giannella M. et al. Ceftazidime-avibactam use for Klebsiella pneumoniae carbapenemase-producing K. pneumoniae Iinfections: a retrospective observational multicenter study. Clin Infect Dis 2021; 73 (09) 1664-1676
    CrossrefPubMedGoogle Scholar
  • 49 Goncette V, Layios N, Descy J, Frippiat F. Continuous infusion, therapeutic drug monitoring and outpatient parenteral antimicrobial therapy with ceftazidime/avibactam: a retrospective cohort study. J Glob Antimicrob Resist 2021; 26: 15-19
    CrossrefPubMedGoogle Scholar
  • 50 Thalhammer F, Traunmüller F, El Menyawi I. et al. Continuous infusion versus intermittent administration of meropenem in critically ill patients. J Antimicrob Chemother 1999; 43 (04) 523-527
    CrossrefPubMedGoogle Scholar
  • 51 Ibrahim MM, Tammam TF, Ebaed MED, Sarhan HA, Gad GF, Hussein AK. Extended infusion versus intermittent infusion of imipenem in the treatment of ventilator-associated pneumonia. Drug Des Devel Ther 2017; 11: 2677-2682
    CrossrefPubMedGoogle Scholar
  • 52 Lorente L, Lorenzo L, Martín MM, Jiménez A, Mora ML. Meropenem by continuous versus intermittent infusion in ventilator-associated pneumonia due to gram-negative bacilli. Ann Pharmacother 2006; 40 (02) 219-223
    CrossrefPubMedGoogle Scholar
  • 53 Drusano GL, Lodise TP, Melnick D. et al. Meropenem penetration into epithelial lining fluid in mice and humans and delineation of exposure targets. Antimicrob Agents Chemother 2011; 55 (07) 3406-3412
    CrossrefPubMedGoogle Scholar
  • 54 Lodise TP, Sorgel F, Melnick D, Mason B, Kinzig M, Drusano GL. Penetration of meropenem into epithelial lining fluid of patients with ventilator-associated pneumonia. Antimicrob Agents Chemother 2011; 55 (04) 1606-1610
    CrossrefPubMedGoogle Scholar
  • 55 Katsube T, Echols R, Arjona Ferreira JC, Krenz HK, Berg JK, Galloway C. Cefiderocol, a siderophore cephalosporin for gram-negative bacterial infections: pharmacokinetics and safety in subjects with renal impairment. J Clin Pharmacol 2017; 57 (05) 584-591
    CrossrefPubMedGoogle Scholar
  • 56 Saisho Y, Katsube T, White S, Fukase H, Shimada J. Pharmacokinetics, safety, and tolerability of cefiderocol, a novel siderophore cephalosporin for gram-negative bacteria, in healthy subjects. Antimicrob Agents Chemother 2018; 62 (03) e02163-e17
    CrossrefPubMedGoogle Scholar
  • 57 Katsube T, Saisho Y, Shimada J, Furuie H. Intrapulmonary pharmacokinetics of cefiderocol, a novel siderophore cephalosporin, in healthy adult subjects. J Antimicrob Chemother 2019; 74 (07) 1971-1974
    CrossrefPubMedGoogle Scholar
  • 58 Katsube T, Nicolau DP, Rodvold KA. et al. Intrapulmonary pharmacokinetic profile of cefiderocol in mechanically ventilated patients with pneumonia. J Antimicrob Chemother 2021; 76 (11) 2902-2905
    CrossrefPubMedGoogle Scholar
  • 59 Mulder MB, Eidelson SA, Sussman MS. et al. Risk factors and clinical outcomes associated with augmented renal clearance in trauma patients. J Surg Res 2019; 244: 477-483
    CrossrefPubMedGoogle Scholar
  • 60 Baptista JP, Martins PJ, Marques M, Pimentel JM. Prevalence and risk factors for augmented renal clearance in a population of critically ill patients. J Intensive Care Med 2020; 35 (10) 1044-1052
    CrossrefPubMedGoogle Scholar
  • 61 Udy AA, Roberts JA, Shorr AF, Boots RJ, Lipman J. Augmented renal clearance in septic and traumatized patients with normal plasma creatinine concentrations: identifying at-risk patients. Crit Care 2013; 17 (01) R35
    CrossrefPubMedGoogle Scholar
  • 62 Chen IH, Nicolau DP. Augmented renal clearance and how to augment antibiotic dosing. Antibiotics (Basel) 2020; 9 (07) 393
    CrossrefPubMedGoogle Scholar
  • 63 Cook AM, Hatton-Kolpek J. Augmented renal clearance. Pharmacotherapy 2019; 39 (03) 346-354
    CrossrefPubMedGoogle Scholar
  • 64 Huttner A, Von Dach E, Renzoni A. et al. Augmented renal clearance, low β-lactam concentrations and clinical outcomes in the critically ill: an observational prospective cohort study. Int J Antimicrob Agents 2015; 45 (04) 385-392
    CrossrefPubMedGoogle Scholar
  • 65 Udy AA, Varghese JM, Altukroni M. et al. Subtherapeutic initial β-lactam concentrations in select critically ill patients: association between augmented renal clearance and low trough drug concentrations. Chest 2012; 142 (01) 30-39
    CrossrefPubMedGoogle Scholar
  • 66 Claus BO, Hoste EA, Colpaert K, Robays H, Decruyenaere J, De Waele JJ. Augmented renal clearance is a common finding with worse clinical outcome in critically ill patients receiving antimicrobial therapy. J Crit Care 2013; 28 (05) 695-700
    CrossrefPubMedGoogle Scholar
  • 67 Carrie C, Bentejac M, Cottenceau V. et al. Association between augmented renal clearance and clinical failure of antibiotic treatment in brain-injured patients with ventilator-acquired pneumonia: a preliminary study. Anaesth Crit Care Pain Med 2018; 37 (01) 35-41
    CrossrefPubMedGoogle Scholar
  • 68 Carrié C, Chadefaux G, Sauvage N. et al. Increased β-Lactams dosing regimens improve clinical outcome in critically ill patients with augmented renal clearance treated for a first episode of hospital or ventilator-acquired pneumonia: a before and after study. Crit Care 2019; 23 (01) 379
    CrossrefPubMedGoogle Scholar
  • 69 He J, Yang ZT, Qian X. et al. A higher dose of vancomycin is needed in critically ill patients with augmented renal clearance. Transl Androl Urol 2020; 9 (05) 2166-2171
    CrossrefPubMedGoogle Scholar
  • 70 Béranger A, Benaboud S, Urien S. et al. Piperacillin population pharmacokinetics and dosing regimen optimization in critically ill children with normal and augmented renal clearance. Clin Pharmacokinet 2019; 58 (02) 223-233
    CrossrefPubMedGoogle Scholar
  • 71 Udy AA, Dulhunty JM, Roberts JA. et al; BLING-II Investigators, ANZICS Clinical Trials Group. Association between augmented renal clearance and clinical outcomes in patients receiving β-lactam antibiotic therapy by continuous or intermittent infusion: a nested cohort study of the BLING-II randomised, placebo-controlled, clinical trial. Int J Antimicrob Agents 2017; 49 (05) 624-630
    CrossrefPubMedGoogle Scholar
  • 72 Nicolau DP, De Waele J, Kuti JL. et al. Pharmacokinetics and pharmacodynamics of ceftolozane/tazobactam in critically ill patients with augmented renal clearance. Int J Antimicrob Agents 2021; 57 (04) 106299
    CrossrefPubMedGoogle Scholar
  • 73 Chen LF, Losada MC, Du J, DeRyke CA, Patel M, Paschke A. Imipenem/Cilastatin/Relebactam Efficacy, Safety, and Probability of Target Attainment in Adults With Hospital-Acquired or Ventilator-Associated Bacterial Pneumonia and Renal Impairment or Augmented Renal Clearance. ECCMID e-learning. 2021 Poster #655
    PubMedGoogle Scholar
  • 74 Fratoni AJ, Nicolau DP, Kuti JL. Imipenem-Cilastatin-Relebactam (I/R) Pharmacokinetics (PK) in Critically Ill Patients with Augmented Renal Clearance (ARC). IDWeek 2021, September 29 to October 3 2021
    PubMedGoogle Scholar
  • 75 Tandukar S, Palevsky PM. Continuous renal replacement therapy: who, when, why, and how. Chest 2019; 155 (03) 626-638
    CrossrefPubMedGoogle Scholar
  • 76 Trotman RL, Williamson JC, Shoemaker DM, Salzer WL. Antibiotic dosing in critically ill adult patients receiving continuous renal replacement therapy. Clin Infect Dis 2005; 41 (08) 1159-1166
    CrossrefPubMedGoogle Scholar
  • 77 Honore PM, Jacobs R, De Waele E, Spapen HD. Applying pharmacokinetic/pharmacodynamic principles for optimizing antimicrobial therapy during continuous renal replacement therapy. Anaesthesiol Intensive Ther 2017; 49 (05) 412-418
    CrossrefPubMedGoogle Scholar
  • 78 Seyler L, Cotton F, Taccone FS. et al. Recommended β-lactam regimens are inadequate in septic patients treated with continuous renal replacement therapy. Crit Care 2011; 15 (03) R137
    CrossrefPubMedGoogle Scholar
  • 79 Wilson FP, Bachhuber MA, Caroff D, Adler R, Fish D, Berns J. Low cefepime concentrations during high blood and dialysate flow continuous venovenous hemodialysis. Antimicrob Agents Chemother 2012; 56 (04) 2178-2180
    CrossrefPubMedGoogle Scholar
  • 80 Jamal JA, Economou CJ, Lipman J, Roberts JA. Improving antibiotic dosing in special situations in the ICU: burns, renal replacement therapy and extracorporeal membrane oxygenation. Curr Opin Crit Care 2012; 18 (05) 460-471
    CrossrefPubMedGoogle Scholar
  • 81 Economou CJP, Wong G, McWhinney B, Ungerer JPJ, Lipman J, Roberts JA. Impact of β-lactam antibiotic therapeutic drug monitoring on dose adjustments in critically ill patients undergoing continuous renal replacement therapy. Int J Antimicrob Agents 2017; 49 (05) 589-594
    CrossrefPubMedGoogle Scholar
  • 82 Langgartner J, Vasold A, Glück T, Reng M, Kees F. Pharmacokinetics of meropenem during intermittent and continuous intravenous application in patients treated by continuous renal replacement therapy. Intensive Care Med 2008; 34 (06) 1091-1096
    CrossrefPubMedGoogle Scholar
  • 83 Roger C, Cotta MO, Muller L. et al. Impact of renal replacement modalities on the clearance of piperacillin-tazobactam administered via continuous infusion in critically ill patients. Int J Antimicrob Agents 2017; 50 (02) 227-231
    CrossrefPubMedGoogle Scholar
  • 84 Mariat C, Venet C, Jehl F. et al. Continuous infusion of ceftazidime in critically ill patients undergoing continuous venovenous haemodiafiltration: pharmacokinetic evaluation and dose recommendation. Crit Care 2006; 10 (01) R26
    CrossrefPubMedGoogle Scholar
  • 85 Kuti JL, Nicolau DP. Optimal cefepime and meropenem dosing for ventilator-associated pneumonia patients with reduced renal function: an update to our clinical pathway. J Crit Care 2010; 25 (01) 155-156
    CrossrefPubMedGoogle Scholar
  • 86 Nicasio AM, Eagye KJ, Nicolau DP. et al. Pharmacodynamic-based clinical pathway for empiric antibiotic choice in patients with ventilator-associated pneumonia. J Crit Care 2010; 25 (01) 69-77
    CrossrefPubMedGoogle Scholar
  • 87 Fratoni AJ, Kuti JL, Nicolau DP. Optimised cefiderocol exposures in a successfully treated critically ill patient with polymicrobial Stenotrophomonas maltophilia bacteraemia and pneumonia receiving continuous venovenous haemodiafiltration. Int J Antimicrob Agents 2021; 58 (03) 106395
    CrossrefPubMedGoogle Scholar
  • 88 Abdul-Aziz MH, Alffenaar JC, Bassetti M. et al; Infection Section of European Society of Intensive Care Medicine (ESICM), Pharmacokinetic/pharmacodynamic and Critically Ill Patient Study Groups of European Society of Clinical Microbiology and Infectious Diseases (ESCMID), Infectious Diseases Group of International Association of Therapeutic Drug Monitoring and Clinical Toxicology (IATDMCT), Infections in the ICU and Sepsis Working Group of International Society of Antimicrobial Chemotherapy (ISAC). Antimicrobial therapeutic drug monitoring in critically ill adult patients: a position paper. Intensive Care Med 2020; 46 (06) 1127-1153
    CrossrefPubMedGoogle Scholar